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 Implication for health policy/practice/research/medical education:
Acute and chronic hepatitis are common viral diseases. Since oxidative stress is a common pathogenetic mechanism contributing 
to initiation and progression of hepatic damage in acute and chronic hepatitis, antioxidants represent a good therapeutic strategy 
for the treatment of acute and chronic hepatitis. Therefore, study of this article is recommended to the epidemiologists, hepatolo-
gists, virologists and other researchers who are interested in the ﬁeld of public health.
Context: Oxidative damage due to oxidative stress is the failure of the cell’s defense 
against the deleterious eﬀects of harmful agents by means of its numerous autoprotec-
tive mechanisms. Oxidative stress is a key impairment induced by various conditions, 
including atherosclerosis, hypertension, ischemia-reperfusion, hepatitis, pancreatitis, 
cancer, and neurodegenerative diseases. 
Evidence Acquisition: Oxidative stress is a common pathogenetic mechanism contrib-
uting to the initiation and progression of hepatic damage in cases of inﬂammatory liver 
disorders, including acute and chronic hepatitis. Antioxidant administration is a good 
therapeutic strategy for the treatment of hepatitis.
Results: Our comprehensive review of the literature revealed that contradictory results 
have been obtained with many antioxidants and antioxidant agents.
Conclusion: Since clinical studies to date have generally involved testing of the eﬀects of 
antioxidant mixtures containing more than 2 antioxidants and also have been limited 
because of toxic eﬀects of high doses of some antioxidants, antioxidant therapy for acute 
and chronic hepatitis needs further study.
Copyright  c 2012 Kowsar Corp. All rights reserved.
* Corresponding author: Mukaddes Esrefoglu, Department of Histology 
and Embryology, Medical Faculty, Bezmialem Vakif University, Istanbul   
Turkey. Tel: +90-2124531700, Fax: +90-5332326, 
E-mail: drmukaddes@hotmail.com
DOI: 10.5812/hepatmon.837
Copyright  c2012 Kowsar Corp. All rights reserved.
1. Context
1.1. What is Oxidative Stress?
Oxidative damage due to oxidative stress is the failure 
of the cell’s defense against the deleterious eﬀects of 
harmful agents. The cell has numerous protective de-
fense mechanisms against threatening factors that are 
induced by its adaptive mechanisms as well as by an 
increase in  its synthetic and metabolic activities. For 
instance, if the target of the injury-causing agent is pro-
tein synthesis,which may result in a deﬁciency of struc-
tural or the other types of proteins (i.e. enzymes, pumps, 
transport proteins, and channels), the cell increases its 
synthetic activity if the protein synthesis apparatus is 
not damaged. If the target is energy metabolism, which 
may result in energy depletion, the cell increases the 
production of ATP via alternate pathways, such as an-
aerobic glycolysis, unless cellular glycogen content is 
depleted. These are compensatory responses of the cell 
to protect itself from damage and death. If the cell’s de-
fense fails, reversible damage transforms into irrevers-
ible damage,ultimately causing cell death. Most cells can 
tolerate a mild degree of oxidative stress because they 
have suﬃcient antioxidant defense capacity and repair 
systems that recognize and remove molecules damaged 
by oxidation. Cells generate energy by reducing molecu-
lar oxygen to water. During this process, small amounts 161 Hepat Mon. 2012
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of partially reduced reactive oxygen species (ROS) are 
produced as a byproduct of mitochondrial respiration. 
Some of these are free radicals that can damage many 
components of cells, including lipids, proteins, and nu-
cleic acids (1, 2). Physiological levels of ROS are beneﬁcial 
for cells. ROS can regulate transcription by activating 
the transcription of speciﬁc genes and can act in the im-
mune system as eﬀector molecules against pathogens. 
Many components of the cell, including mitochondria, 
endoplasmic reticulum, peroxisomes, membranes, and 
cytosol, can be sources of ROS. In general, there is a bal-
ance between the production of ROS and cellular antioxi-
dant agents. The accumulation of low to moderate levels 
of ROS is generally counterbalanced by the cell’s endog-
enous antioxidant defense system. Antioxidant agents 
act jointly to remove various ROS produced by free radi-
cal reactions. Indeed, antioxidant activity may be a con-
sequence of ROS production. If the amount of ROS in-
creases, and if these products destroy the apparatus by 
which antioxidant agents are produced, the cellular de-
fense system is eventually incapacitated. It appears that 
higher levels of ROS induce necrotic cell death whereas 
lower levels lead to apoptosis.
1.2. How Can ROS Induce Hepatic Damage?
Oxidative stress is a key eﬀect of various conditions, in-
cluding anoxic/reoxygenation injury, autoimmune hep-
atitis, viral hepatitis, and alcoholic hepatitis (3). Liver 
damage ranging from acute hepatitis to hepatocellular 
carcinoma is a result of apoptosis, necrosis, inﬂamma-
tion, immune response, ﬁbrosis, ischemia, altered gene 
expression, and regeneration, all processes that involve 
hepatocytes and Kupﬀer, stellate, and endothelial cells 
(4, 5). Severe oxidative stress leads to hepatocyte necro-
sis, while less severe oxidative stress leads to apoptosis. 
ROS play an important role in the pathogenesis of in-
ﬂammatory diseases, although the detailed mechanisms 
of ROS involvement are still controversial. Stimulation 
with cytokines leads to the generation of ROS by resident 
and inﬁltrating phagocytes and/or intracellularROS gen-
eration in all types of liver cells. In fact,ROS are essential 
for the host-defense functions of phagocytes and can 
modulate the formation of mediators involved in regu-
lating sinusoidal blood ﬂow and liver regeneration (6). 
Intracellular parasitic viruses may remain clinically la-
tent and without reactivation within host cells until the 
cellular redox balance is disturbed. Wide ﬂuctuations in 
incubation periods for hepatitis B and C suggest that the 
viral activity can be determined by the redox state of 
cells. With more severe oxidative stress, the viral replica-
tion is more active with dispersion from lysed or apop-
totic cells. Viruses use host cell synthetic processes for 
replication, leading to the disturbance of the normal 
physiological biochemistry of endoplasmic reticulum 
and mitochondria with augmented ROS generation and 
antioxidant depletion (5). In children with chronic B or C 
hepatitis, low catalase (CAT) and superoxide dismutase 
(SOD) activity and evidence of increased lipid peroxida-
tion indicate inadequate antioxidant defense (7). Detec-
tion of an increase in malondialdehyde (MDA) levels, 
which is a product of lipid peroxidation in hepatitis B vi-
rus (HBV)-infected groups, indicates that oxidative stress 
is increased in HBV infection (8). In acute and chronic ac-
tive viral hepatitis, the markedly reduced plasma gluta-
thione (GSH) levels increase on recovery (9). HBV and 
hepatitis C virus (HCV) cause severe antioxidant deple-
tion, and elevated levels of peroxidation products sec-
ondarily aﬀect immune cells (5). HCV infection is charac-
terized by a systemic oxidative stress that is most likely 
caused by a combination of chronic inﬂammation, iron 
overload, liver damage, and proteins encoded by HCV. 
The increased generation of reactive oxygen and nitro-
gen species, together with the decreased antioxidant de-
fense, promotes the development and progression of 
hepatic and extrahepatic complications of HCV infection 
Although both HCV and HBV cause hepatitis, HCV ap-
pears to be particularly potent at inducing oxidative 
stress, suggesting there are oxidative stress–inducing 
mechanisms that are unique to this virus(10). Continued 
ethanol consumption increases the severity of liver dam-
age, which progresses to frank inﬂammatory hepatitis 
and eventually to cirrhosis in humans and experimental 
baboons (11). This progression is associated with oxida-
tive stress, free radical generation, depletion of protec-
tive antioxidants (α-tocopherol, vitamin A, selenium, 
GSH, glutathione peroxidase [GSHPx]), reduced serum 
and liver zinc content, and hyperzincuria. Acute and 
chronic ethanol consumption increases ROS production, 
lowers cellular antioxidant levels, and enhances oxida-
tive stress in many tissues, especially the liver (12). Chron-
ic ethanol consumption has long been known to repress 
mitochondrial functions(13). The occurrence of DNA 
fragmentation in peripheral blood lymphocytes reﬂects 
a direct genotoxic eﬀect of alcohol, HBV, and/or HCV and 
suggests that the same genotoxic eﬀect may be induced 
in the liver and contribute to hepatocarcinogenesis(14).
ROS, in particular superoxide anion, rapidly react with 
nitric oxide (NO) to form peroxynitrite, which may act as 
a dangerous molecule and induce lipid peroxidation. 
However, the  formation of peroxynitrite may also be a 
protective pathway because through this mechanism 
NO acts as an ROS scavenger(4). NO can also derive direct-
ly from cytokine-activated neutrophils and lymphocytes 
in the circulation. The liver contains an inducible form of 
NO-synthase (iNOS) in hepatocytes, cholangiocytes, 
Kupﬀer, and stellate cells, and the endothelial form 
(eNOS) in the endothelial cells (15). In patients with 
chronic HCV infection, a direct correlation between iNOS 
induction and HCV-RNA titer has been documented. 
Therefore, in addition to oxidative stress,nitrosative 
stress may have a relevant role in the pathogenesis of 
chronic viral hepatitis (16). NO plays a role in the patho-
physiology of viral (chronic hepatitis B and C) and auto-
immune (primary biliary cirrhosis and autoimmune 
hepatitis) liver diseases (17). Mitochondria and cyto-
chrome P450 enzymes are the main sources of ROS in 162 Hepat Mon. 2012
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hepatocytes acutely and/or chronically exposed to injury 
(via drugs, alcohol, viruses, etc.)(4). Phagocytes such as 
macrophages and neutrophils are capable of destroying 
invading microorganisms and removing necrotic and 
cellular debris by producing ROS and releasing proteas-
es. ROS released by neutrophils and other phagocytes 
can cause an intracellular oxidant stress in target cells, 
which can kill hepatocytes within 1–2 h in vivo without 
evidence of lipid peroxidation (18). Recent experiments 
have shown that selective Kupﬀer cell-induced oxidant 
stress can cause hepatocellular injury in isolated per-
fused liver within 1–2 h (19). Indeed, liver inﬂammation is 
initiated by Kupﬀer cells, and it involves the formation 
and release of many inﬂammatory mediators, which re-
cruit neutropils,lymphocytes, and other inﬂammatory 
cells to damaged regions (20). Hepatocytes and inﬁltrat-
ing inﬂammatory cells interact in a complex and multi-
factorial process through soluble mediators, surface re-
ceptors, and adhesion molecules(21). In response to 
hepatocellular stress, pro-inﬂammatory cytokines, e.g., 
interleukin-1, interleukin-6, and tumor necrosis factor 
(TNF)-α are released. These agents stimulate neighboring 
hepatocytes and other nonparenchymal cells (22). Pro-
inﬂammatory cytokines such as TNF-α can induce the for-
mation of ROS in hepatocytes (23), where they can play a 
role in a large variety of activities, including Ca2+ accu-
mulation, circulatory and transport function, NO synthe-
sis and metabolism, cytokine gene expression, caspase 
activity, growth factor synthesis and activity, DNA frag-
mentation, and Na+ inﬂux. (4). ROS can react with fatty 
acid chains of membrane phospholipids. Reaction prod-
ucts are mostly seen on the outer membrane of the mito-
chondria, suggesting that lipid peroxidation occurs 
mainly at the mitochondrial membrane and supporting 
the ﬁnding of remarkable mitochondrial changes in he-
patocytes in alcoholic hepatitis, nonalcoholic steatohep-
atitis(24), and hepatitis C (25). Some of the products of 
lipid peroxidation can lead to loss of integrity, resulting 
in necrosis. It is suggested that to selectively kill hepato-
cytes by lipid peroxidation, a combination of oxidant 
stress, iron mobilization, and depletion of cellular anti-
oxidants is necessary (26). Excessively high levels of iron 
are stored in the hepatocytes of patients with nonalco-
holic steatohepatosis, alcoholic hepatitis, or hepatitis C. 
The over-accumulation of iron causes oxidative stress in 
the hepatocytes (27). It is a fact that certain lipid peroxi-
dation products are potent chemotactic factors for neu-
trophils and can modulate reactive oxygen formation 
(28). Hepatocytes, with their more potent antioxidant 
systems, are less susceptible to oxidant stress than non-
parenchymal cells (29). Kupﬀer cells and endothelial 
cells are more exposed or sensitive to oxidative stress–re-
lated molecules (3). Under inﬂammatory conditions, in 
which activated complement factors stimulate Kupﬀer 
cells to produce reactive oxygen in the hepatic vascula-
ture, complement induces the enhanced sinusoidal re-
lease of GSH from hepatocytes (30). Hepatocytes contain 
about 10% of the total body pool of GSH (31). GSH in the 
space of Disse non-enzymatically reacts with hydrogen 
peroxide, peroxynitrite, and hypochlorous acid (32). It 
also aﬀects the transcription of proinﬂammatory/anti-
inﬂammatory cytokine genes, liver regeneration 
through cytokine-mediated nuclear factor κ binding (NF-
κB) induction, NO bioavailability, and energy metabo-
lism (4). Depletion of GSH may be both a reason for and a 
consequence of liver damage. GSH levels in the liver and 
circulation have been reported to be decreased in pa-
tients with alcoholic and viral cirrhosis and HCV-related 
chronic hepatitis (33, 34). Enhanced production of ROS 
and the altered GSH pool contribute to programmed 
death by activating gene expression for transcription fac-
tors such as NF-κB, leading to up-regulation of proinﬂam-
matory cytokines, chemokines, adhesion molecules, Fas 
ligands, survival genes, etc., which consecutively activate 
the cascade of caspases (apoptosis) or induce the release 
of cytochrome c and the depletion of ATP at the mito-
chondrial level (necrosis) (35, 36). Necrotic cell death is 
linked to the opening of the permeability transition pore 
and the onset of mitochondrial membrane permeability 
transition (MPT) (37), which leads to mitochondrial un-
coupling and loss of membrane potential. A signiﬁcant 
magnitude of oxidant stress causes oxidation of mito-
chondrial NAD(P)H and reactive oxygen formation by 
mitochondria, both of which increase mitochondrial 
free Ca2+ levels(38). The MPT is induced by an increase of 
mitochondrial Ca2+ directly (39) or through the activa-
tion of mitochondrial serine proteases (calpains) (40). In 
addition, cytosolic calpains promote membrane bleb-
bing via degradation of cytoskeleton proteins (41). The 
combination of these events leads to rapid necrotic cell 
death.The induction of the cytochrome P450 enzyme sys-
tem, the endotoxin-induced cytokine expression in 
Kupﬀer cells, and neutrophil inﬁltration further en-
hance the production of ROS and deplete ATP reserves in 
hepatocytes. ROS generated from neutrophils migrate 
into the hepatocytes and potentiates the shift of apopto-
sis to necrosis (18). Another contribution to cell death 
derives from the adhesion of cytotoxic lymphocytes that 
release proteases and perforin from cytotoxic granules, 
particularly in presence of ROS, which mediate the lym-
phocyte-Fas/Fas ligand interaction (42). 
2. Evidence Acquisition
2.1. Are Antioxidants Eﬀective in the Management of 
Acute and Chronic Hepatitis?
Since oxidative stress is a common pathogenetic mech-
anism contributing to initiation and progression of he-
patic damage in inﬂammatory liver disorders, includ-
ing acute and chronic hepatitis, antioxidants represent 
a good therapeutic strategy for the treatment of acute 
and chronic hepatitis. Many natural compounds have 
the ability to scavenge ROS, thereby reducing oxidative 
stress directly, or they may oﬀer an indirect protection 
by activating endogenous defense systems (43). Induc-
tion of important enzymes in a cell defense system, e.g., 163 Hepat Mon. 2012
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SOD, CAT,GSHPx, and others, seems conceivable because 
fully functional cells are more likely to respond than ne-
crotic and damaged cells (44). Signiﬁcant reductions in 
serum levels of vitamins such as β-carotene, vitamin C, 
vitamin D, and vitamin E in patients with chronic viral 
hepatitis have been reported (45-47), but the underly-
ing mechanisms have not been elucidated. Because GSH; 
ubiquinol; Zn; selenium; GSHPx; CAT; SOD; β carotene; 
and vitamins A, C, and E can be seriously depleted by the 
time viral hepatitis is diagnosed, their stores require ur-
gent replenishment. Therefore, large doses of primary 
antioxidants should be the initial therapy to restore and 
thereafter to maintain serum and tissue concentrations 
at high normal values. Acute toxic and viral hepatitis are 
similar in histological features and in both situations the 
hepatic damage is due to oxidative stress, generation of 
free radicals, and lipid peroxidation. Thus management 
of viral hepatitis, as in the case of toxic hepatitis, neces-
sitates early restoration of optimal concentrations of 
essential antioxidants in the liver and plasma. However, 
contradictory results have been obtained with some of 
the antioxidants; therefore, these antioxidant agents 
need to studied further. Moreover, the results of a meta-
analysis in which beta carotene; vitamins A, C, and E; and 
selenium levels were assessed in 1225 participants of 20 
randomized trials showed no evidence to support or 
refute the eﬀectiveness of antioxidant supplements in 
patients with autoimmune liver diseases, viral hepatitis, 
alcoholic liver disease, and cirrhosis (48). The results of-
clinical studies about the eﬃciency of vitamins for acute 
and chronic viral hepatitis are generally controversial, 
and to determine whether a vitamin is beneﬁcial is diﬃ-
cult. Although the antiviral activity of vitamins in chron-
ic hepatitis B or C has notbeen demonstrated, some data 
indicate that vitamin E is able to reduce inﬂammation-in-
duced oxidative stress and to restore immune response. 
To date, none of the vitamins havebeen recommended 
for the treatment of chronic viral hepatitis (49). In fact, 
it is known that vitamin E enhances HCV RNA replication 
(50). However, vitamin D2 inhibits HCV RNA replication 
(51). Antioxidant supplements had no signiﬁcant eﬀect 
on end-of-treatment virological response in patients 
with chronic hepatitis B or chronic hepatitis C. Addition-
ally, the antioxidant supplements had no signiﬁcant 
eﬀect on the sustained virological response in patients 
with chronic hepatitis C (48). 
Vitamins C, A, and E are the most important antioxi-
dants associated with cell-mediated immunity and toxic 
hepatitis (52). Vitamin C protects cell components from 
free radical damage by reducing water soluble radicals, 
scavenging lipid-peroxidation–derived radicals, or re-
ducing tocopherol radicals to tocopherol (53). In human 
tissues, vitamin E is the principal lipid soluble chain-
breaking antioxidant in mitochondria, microsomes, and 
lipoproteins (54). Antioxidant therapy should include 
vitamins A, C, and E in combination (acting synergisti-
cally) at doses up to 6 times the recommended daily al-
lowances, enhancing host immunity and resistance to 
pathogenic bacteria, viruses, and Chlamydia, partly by 
antioxidant eﬀects and by facilitating optimal function-
ing of the host immune response (55, 56). 
4. Results
Selenium is more eﬀective in preventing free radical 
production than vitamin E. Additionally vitamin C recon-
stitutes reduced vitamin E (57). The important oxidation–
reduction reactions of selenium compounds involve per-
oxide decomposition, free radical scavenging, and 
molecular repair of damaged sites (54). Supplementa-
tion with a combination of selenium, ascorbic acid, beta-
carotene, and alpha-tocopherol has been reported to be 
helpful ininhibiting the development of liver injury in-
duced by D-galactosamine (58). It has been shown that 
prophylactic administration of ubiquinone protects rat 
liver from toxic damage by D-galactosamine on both ul-
trastructural and cellular levels. Ubiquinone exerts an 
antioxidant eﬀect, blocking the induction of lipid perox-
idation both in intact and hepatic rats (41). Beta-carotene, 
vitamin D2, and linoleic acid possessed anti-HCV activity 
in a cell culture system, and these nutrients were there-
fore considered potential candidates for enhancing the 
eﬀects of interferon therapy (59). Ebselen, an organosele-
nium compound and GSHPx analog, decreases oxidative 
stress and protects against stroke clinically. It also pre-
vents early alcohol-induced liver injury, most likely by 
preventing oxidative stress, which decreases inﬂamma-
tion (60). A large number of antioxidant interventions 
have been used against inﬂammatory liver injuries. 
Some of the antioxidant strategies have included treat-
ment with important antioxidant enzymes in the cell 
defense system, including SOD; CAT; and GSH; vitamins A, 
C, and E; trace elements such as zinc and selenium; anti-
oxidants isolated from plant and animal sources, includ-
ing ﬂavonoids (i.e. Silybummarianum, quercetin, kaemp-
ferol, and apigenin); phenolic compounds (i.e. canolol, 
green tea, rosemary, resveratrol), chemical antioxidants 
such as tirilazadmesylate; and ebselen, tannins, couma-
rins, xanthones, and alkaloids. Many natural compounds 
have the ability to scavenge ROS, thereby reducing oxida-
tive stress directly, or they may oﬀer indirect protection 
by activating endogenous defense systems (43). Induc-
tion of important enzymes in the cell defense system, 
e.g.,SOD, CAT  and GSHPx, is possible because fully func-
tional cells are more likely to respond than necrotic and 
damaged cells (44). Flavonoids are eﬃcient suppressors 
of oxygen radicals because of their radical scavenging 
properties and are inducers of the cellular antioxidant 
system (29, 43, 61, 62). Vitamin E, vitamin C, ubiquinol, 
β-carotene, uric acid, thiols, and bilirubin also act as 
chain-breaking antioxidants (5). Indeed, antioxidant 
drugs such as GSH, silymarin, vitamin E, and N-acetyl-
cysteine can reduce oxidative and nitrosative stress, in-
crease the GSH pool, and improve the activity of P450-
enzymes, counteracting the progression of liver disease 
in some patients (63-65). However, a randomized trial of 
antioxidant therapy, including N-acetylcysteine for 1 164 Hepat Mon. 2012
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week, and vitamins A–E, biotin, selenium, zinc, manga-
nese, copper, magnesium, folic acid, and coenzyme Q in 
acute alcoholic hepatitis did not improve 6-month sur-
vival in patients with severe alcoholic hepatitis (66). 
Nonetheless, the plasma concentrations of vitamins A, D, 
E, folate (B12), thiamine (B1), and pyridoxine (B6) are low 
in patients with acute alcoholic hepatitis (67). Recently, 
Phillips et al. (68) conducted a controlled trial in which 
the eﬀects of prednisone were compared with those of 
an antioxidant cocktail (containing vitamins A, C, and E; 
selenium; allopurinol; desferrioxamine; and N-acetylcys-
teine) with intralipid as a membrane stabilizer. Antioxi-
dants had an adverse eﬀect on 30-day mortality. Mezey et 
al. (69)found no beneﬁcial eﬀect of vitamin E on liver 
function in patients with mild to moderate alcoholic 
hepatitis. Overall, the present data do not support anti-
oxidants as a curative therapy for severe alcoholic hepati-
tis. However, Cox et al. (70) studied a combination of anti-
oxidants (vitamins C and E) and ursodeoxycholic acid, a 
membrane-stabilizing agent, and found it as eﬀective as 
corticosteroids.N-acetylcysteine can be safely adminis-
tered to patients with fulminant liver failure of various 
causes and has been reported to reduce mortality in pa-
tients with alcoholic hepatitis (71). De moine et al. (72) re-
ported that N-acetylcysteine could be safely adminis-
tered in cirrhosis patients with alcoholic hepatitis, with 
an improvement in some biological parameters (includ-
ing signiﬁcant decreases in aspartate transaminase, alka-
line phosphatase, and prothrombin time). Zinc supple-
mentation prevented hepatocyte apoptosis in mice 
subjected to long-term ethanol exposure, and the action 
of zinc is likely through suppression of oxidative stress 
and death receptor-mediated pathways (73). Additional-
ly, lecithin, vitamin-B complex, and tocopheryl acetate 
treatment have been reported to reduce oxidative stress 
by controlling ethanol-induced immunomodulatory ac-
tivities and supporting antioxidant systems (74).Silyma-
rin supplementation to antiviral therapy reduced oxida-
tive stress in chronic hepatitis C patients (75). A 
combination of 3 potent antioxidants (alpha-lipoic acid, 
silymarin, and selenium) induced marked improvement 
in clinical, laboratory, and histological test results of 
chronic HCV patients (76, 77). In a study involving 170 pa-
tients, 420 mg/day of silymarin administered for an aver-
age of 41 months resulted in a signiﬁcant improvement 
in survival (78, 79). Silymarin inhibits HCV-induced oxi-
dative stress by its antiviral action, reducing HCV replica-
tion, and by its antioxidative action, independently of 
suppression of virus. Because silymarin inhibits oxida-
tive stress independently of suppression of virus activity, 
it is possible that the hepatoprotective actions of silyma-
rin may extend to liver diseases of nonviral origin (80). 
Silymarin has been reported to protect liver cells from a 
wide variety of toxins, including acetaminophen, etha-
nol, carbon tetrachloride, and D-galactosamine, as well 
as from ischemic injury, radiation, iron toxicity, and viral 
hepatitis (81, 82). A combination of antiviral and antioxi-
dative therapies, including silymarin, ascorbic acid, li-
poic acid, and alpha-tocopherol, may enhance the overall 
response rate in the patients with chronic hepatitis C 
(83). Resveratrol, a dietary polyphenol, has been shown 
to possess potent antioxidant as well as anti-inﬂammato-
ry properties and to mediate induction of antioxidant 
enzymes and modulate lipid metabolism while attenuat-
ing hepatic lipid peroxidation (84). It increases hepatic 
GSH content, scavenges free radicals, and inhibits the 
transcription of NF-κB, which induces inﬂammation 
(85). Resveratrol provides protection against liver dam-
age produced by several hepatotoxins, including acet-
aminophen and ethanol (86, 87). However, resveratrol is 
not suitable as an antioxidant therapy for chronic hepati-
tis C because it signiﬁcantly enhances HCV RNA replica-
tion (50). Quercetin is a ﬂavonoid antioxidant. Treatment 
of HCV infection with quercetin in tissue culture lowered 
intracellular viral accumulation and infectious particle 
production. Quercetin inhibits viral protein production 
independently of viral genome replication. Quercetin 
may allow for dissection of the viral life cycle and has po-
tential therapeutic use to reduce virus production with 
low associated toxicity (88). Additionally, dihydroquerce-
tin has been shown to be beneﬁcial as a hepatoprotective 
substance in the treatment of toxic hepatitis and liver ﬁ-
brosis by enhancing antioxidant enzyme activity and de-
creasing the pro-oxidant eﬀect (89, 90). Recently a mito-
chondria-targeted antioxidant—mitoquinone—has been 
reported to be eﬀective indecreasing liver damage in pa-
tients with chronic hepatitis C (91). This was the ﬁrst re-
port of a potential clinical beneﬁt from the use of mito-
chondria-targeted antioxidants in humans. Ideally, a 
mitochondria-targeted antioxidant will be a pharmaceu-
tically tractable, stable, small molecule with acceptable 
oral bioavailability that is selectively taken up by mito-
chondria within organs, where it is able to control oxida-
tive damage, and in the ideal situation, can be recycled to 
the active antioxidant form (92).
4. Conclusions
Since contradictory results regarding many antioxi-
dants exist, and clinical studies, to date, have generally 
involvedtesting the eﬀects of antioxidant combinations 
containing more than 2 antioxidants and have been lim-
ited because of toxic eﬀects of high doses of some anti-
oxidants, antioxidant therapy in individuals with acute 
and chronic hepatitis needs further evaluation.
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